In the Claims:

1. (Currently amended) A dry powder pharmaceutical composition for inhalation therapy comprising salmeterol or a pharmaceutically acceptable salt thereof and fluticasone propionate, an excipient and a derivatized carbohydrate in particulate form wherein the derivatized carbohydrate has an aerodynamic size in the range 1 - 20 μm.

2. (Previously Presented) A dry powder pharmaceutical composition according to claim 1 in which salmeterol is present as its 1-hydroxy-2-naphthoate salt.

3. (Previously Presented) A dry powder pharmaceutical composition according to claim 1 in which the derivatized carbohydrate is a mono or di-saccharide in which at least one hydroxyl group of the carbohydrate group is substituted with a hydrophobic moiety via either ester or ethers linkages.

4. (Previously Presented) A dry powder pharmaceutical composition according to claim 1 in which the derivatized carbohydrate is a carbohydrate selected from fructose, glucose, mannitol, maltose, mannitol, trehalose, cellobiose, lactose and sucrose in which at least one hydroxyl group of said carbohydrate is substituted by a straight or branched hydrocarbon chain comprising up to 20 carbon atoms.

5. (Previously Presented) A dry powder pharmaceutical composition according to claim 1 in which the derivatized carbohydrate is selected from the group consisting of cellobiose octaacetate, sucrose octaacetate, glucose pentacetate, mannitol hexaacetate and trehalose octaacetate.

6. (Previously Presented) A dry powder pharmaceutical composition according to claim 1 in which the derivatized carbohydrate is α-D cellobiose octaacetate.

7. (Previously Presented) A dry powder pharmaceutical composition according to claim 1 in which the derivatized carbohydrate is present at a concentration of less than 10% of the total composition.

8. (Cancelled).

9. (Previously Presented) A dry powder pharmaceutical composition according to claim 1 in which one component of the excipient has a particle size of less than 15μm (the fine excipient component) and another component of the excipient has a particle size of greater than 20μm but lower than 150μm (the coarse excipient component).

10. (Original) A dry powder pharmaceutical composition according to claim 9 in which the fine and coarse excipient components are both lactose.

11. (Previously Presented) A dry powder pharmaceutical composition according to claim 1 for use in therapy.

12. (Withdrawn) A method of treatment or prophylaxis of respiratory disorders which comprises administering to a patient in need thereof a dry powder pharmaceutical composition according to claim 1.

13. (Cancelled)

14. (Withdrawn) An inhalation device containing therein a dry powder pharmaceutical composition according to claim 1.

15. (Original) An inhalation device according to claim 14 in which the dry powder pharmaceutical composition is released from a pre-metered unit medicament pack.

16. (Withdrawn) A medicament pack for use in an inhalation device which comprises an elongate strip formed from a base sheet having a plurality of

recesses spaced along its length and a lid sheet hermetically but peelably sealed thereto to define a plurality of containers, each container having therein an inhalable composition according to claim 1.

17. (Withdrawn) A medicament pack according to claim 16 wherein the strip is sufficiently flexible to be wound into a roll.

18. (Withdrawn) A medicament pack according to claim 16 wherein the lid sheet and base sheet have leading end portions which are not sealed to one another.

19. (Withdrawn) A medicament pack according to claim 18 wherein at least one of the said leading end portions is constructed to be attached to a winding means.

20. (Withdrawn) A medicament pack according to claim 16 wherein the hermetic seal between the base and lid sheets extends over their whole width.

21. (Withdrawn) A medicament pack according to claim 16 wherein the lid sheet may be peeled from the base sheet in a longitudinal direction from a first end of the said base sheet.

22. (Withdrawn) A method of improving stability performance in dry powder pharmaceutical compositions comprising salmeterol or a pharmaceutically acceptable salt thereof and fluticasone propionate, said method including the step of including in said composition a particulate derivatized carbohydrate.

23. (Withdrawn) A method of eliminating or reducing the detrimental effect on fine particle dose experienced during storage of a dry powder pharmaceutical composition comprising salmeterol or a pharmaceutically acceptable salt thereof and fluticasone propionate, wherein said method comprises the step of including a particulate derivatized carbohydrate in said dry powder pharmaceutical compositions.

24. (Withdrawn) The method of claim 22 in which the particulate derivatized carbohydrate is cellobiose octaacetate.

25. (Withdrawn) The method of claim 23 in which the particulate derivatized carbohydrate is cellobiose octaacetate.